Reaction
Myeloid Leukaemia reporting signals
As of the last recalculation, Myeloid Leukaemia appears in 499 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is IFOSFAMIDE (PRR 82.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ifosfamide | 39 | 82.0 | 82.2 |
| Vincristine Sulfate | 30 | 45.4 | 45.4 |
| Imatinib | 18 | 44.1 | 44.2 |
| Doxorubicin | 77 | 42.4 | 42.5 |
| Fludarabine Phosphate | 36 | 41.1 | 41.1 |
| Azacitidine For | 16 | 37.9 | 37.9 |
| Hydroxyurea | 18 | 36.8 | 36.8 |
| Mesna Injection | 7 | 35.8 | 35.9 |
| Mesna | 7 | 35.2 | 35.2 |
| Etoposide | 54 | 34.2 | 34.3 |
| Azacitidine | 23 | 33.8 | 33.9 |
| Cytarabine | 41 | 30.9 | 30.9 |
| Blinatumomab | 7 | 28.4 | 28.4 |
| Cyclophosphamide Injection, Solution | 97 | 28.1 | 28.1 |
| Cyclophosphamide | 97 | 28.1 | 28.1 |
| Cyclophosphamide For Injection | 97 | 28.1 | 28.1 |
| Olaparib | 11 | 22.4 | 22.4 |
| Doxorubicin Hydrochloride | 16 | 21.1 | 21.1 |
| Bleomycin Sulfate | 5 | 20.4 | 20.4 |
| Dasatinib | 17 | 19.7 | 19.7 |